Intelligent Health.tech Issue 22 | Page 10

NEWS

KEY FINDINGS OF THE SANS INSTITUTE 2024 CYBERTHREAT INTELLIGENCE

SURVEY UNVEILED

SANS Institute , a global leader in cybersecurity training , has published the 2024 Cyberthreat Intelligence ( CTI )

Survey , authored by SANS Certified Instructor Rebekah Brown and SANS Instructor Candidate Andreas Sfakianakis .
This year ’ s report presents a focus on the significant influence of geopolitical events , the burgeoning role of AI and the emerging dominance of threat hunting within CTI teams .
“ The increasing frequency and complexity of global conflicts have made it essential for CTI teams to broaden their focus beyond internal issues ,” said Brown . “ Our survey shows that 77.5 % of respondents recognise the significant impact of geopolitics on their intelligence requirements , highlighting the need for adaptive and informed responses to external threats .
“ AI is becoming a crucial tool for CTI teams , helping analysts prioritise and process vast amounts of information through advanced scoring and summarisation techniques .”
However , Brown also highlighted the growing concern about the adversarial use of AI , stressing the importance of preparing for AI-driven threats .
For the first time , threat hunting has emerged as the top use case for CTI . This proactive approach to detecting unidentified threats has seen substantial reliance on the MITRE ATT & CK framework , with over 95 % of respondents utilising it for categorising and communicating tactics , techniques and procedures ( TTPs ).
“ The prominence of threat hunting reflects a strategic shift in how organisations are leveraging CTI ,” said Sfakianakis . “ This approach not only enhances detection capabilities but also strengthens overall security posture .”

POTENTIAL ADD-ON TREATMENT FOR PATIENTS WITH PARKINSON ’ S DISEASE : STIMVIA COMPLETES PILOT STUDY AND ANNOUNCES PROMISING INITIAL RESULTS

Stimvia , a pioneering medical technology company specialising in neuromodulation for chronic disease treatment , has successfully completed its pilot study focused on Parkinson ’ s Disease ( PD ) and is expecting promising results .

“ We are pleased to share preliminary findings indicating promising results . Patients have reported improvements in both the number of Parkinson ’ s disease symptoms and their overall quality of life . Furthermore , we have observed a notable reduction in resting tremors . While the precise data are still under rigorous evaluation , we remain cautiously optimistic about the potential implications of these outcomes ,” said Proffessor David Skoloudik , MD , Ph . D ., FESO , FEAN , the study ’ s lead and Vice-Dean for Science and Research at the Medical Faculty of Ostrava University .
Twelve patients with Parkinson ’ s Disease who met inclusion criteria participated in the study . For six weeks , patients used the URIS device for thirty-minute stimulation sessions daily . Following this phase , patients went six weeks without stimulation , during which they continued to be monitored to assess whether any positive effects persisted after the treatment ended .
“ Since the URIS technology demonstrated a positive impact in treating Parkinson ’ s Disease , Stimvia plans substantial investment in further clinical trials to validate the method ’ s efficacy and safety . We believe our technology can introduce new , additive treatment modalities for millions of patients who currently have no other options , potentially offering a positive disease-modifying impact on those with Parkinson ’ s disease ,” added Lukas Doskocil , CEO of Stimvia .
10 www . intelligenthealth . tech